Are cannabinoids safe and effective for treatment of patients with rheumatoid arthritis?
Metadata[+] Show full item record
Sativex® (an oral-mucosal cannabinoid spray containing tetrahydrocannabinol and cannabidiol), as an adjuvant treatment, improves morning pain with movement and at rest, and sleep quality, with minimal adverse events, for patients with rheumatoid arthritis (RA) refractory to standard therapy. Morning stiffness was not significantly improved. (SOR: B, based on a single small RCT.) Sativex is not yet available in the United States.
Evidence Based Practice 13(10): 22.